Spectrum Pharmaceuticals: Bringing Hope for Patients with EGFR Non-Small-Cell Lung Cancer with Exon 20 Insertion Mutations

Spectrum Pharmaceuticals (SPPI) announced an oral presentation of interim data from a Phase 2 clinical study evaluating the pan-HER inhibitor poziotinib in EGFR Exon 20 Mutant Non-Small-Cell Lung Cancer (NSCLC) by scientists from the MD Anderson Cancer Center. The data were presented at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan on October 15-18, 2017.

The trial results from Poziotinib demonstrated evidence of significant anticancer activity in NSCLC patients with EGFR exon 20 insertion mutations. Interim data showed an Objective Response Rate of 73%. 

This content is for paid subscribers.
Please click here to subscribe or here to log in.